• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Opioid Crisis

FDA, Doctors Knew Fentanyl Was Overprescribed, Study Shows

By
Brittany Shoot
Brittany Shoot
Down Arrow Button Icon
By
Brittany Shoot
Brittany Shoot
Down Arrow Button Icon
February 19, 2019, 5:43 PM ET

Regulators at the United States Food and Drug Administration (FDA), as well as physicians, pharmacists, and drug company representatives, all knew that existing safeguards were not stopping the illicit spread of the powerful synthetic opioid fentanyl, according to research published in JAMA Network on Tuesday. This allowed people who should not have had access to the drug, which is 50 to 100 times as potent as morphine and often laced with or sold as heroin, to get it. Overall, the study authors concluded that 34.6% to 55.4% of those prescribed the drug should not have been.

The analysis was based on 4,877 pages of FDA documents that were obtained through a Freedom of Information Act (FOIA) request. As the Washington Post notes, a FOIA request is an unusual aspect of this medical journal paper, which is more commonly based on a controlled study rather than qualitative analysis of records. But this study, which looks at how safeguards failed to keep the highly addictive painkiller from becoming widely available, shows the necessity for strict measures to keep the potent drug from the general public.

Fentanyl’s widespread use and misuse has been noted in recent months. In 2018, fentanyl was responsible for more than half of all overdose deaths, a striking uptick. The painkiller is so powerful, the Drug Enforcement Agency (DEA) even issued new guidelines for first responders that might encounter a fentanyl-related overdose, noting they could be fatally exposed if they come in contact with even a tiny amount of the substance.

About the Author
By Brittany Shoot
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.